|
13.01.2025 17:00:00
|
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Company announcement – No. 1 / 2025
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Copenhagen, Denmark, January 13, 2025 – Zealand Pharma A/S ("Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.
Please see the attached file(s).
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.
Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand’s business and activities, please visit?www.zealandpharma.com.
Contact:
Neshat Ahmadi
Investor Relations Manager
Email: neahmadi@zealandpharma.com
Adam Lange
Investor Relations Officer
Email: alange@zealandpharma.com
Anna Krassowska, PhD
Vice President, Investor Relations & Corporate Communications
Email: akrassowska@zealandpharma.com
Attachments
Nachrichten zu Zealand Pharma A-S
|
20.12.24 |
FDA drug rejection hits Zealand Pharma shares (Financial Times) | |
|
19.12.24 |
U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome (GlobeNewswire) | |
|
06.11.24 |
Ausblick: Zealand Pharma A-S legt Zahlen zum jüngsten Quartal vor (finanzen.net) | |
|
23.10.24 |
Erste Schätzungen: Zealand Pharma A-S präsentiert Bilanzzahlen zum jüngsten Jahresviertel (finanzen.net) | |
|
14.08.24 |
Ausblick: Zealand Pharma A-S stellt Zahlen zum jüngsten Quartal vor (finanzen.net) | |
|
31.07.24 |
Erste Schätzungen: Zealand Pharma A-S präsentiert Bilanzzahlen zum jüngsten Jahresviertel (finanzen.net) |
Im BX Morningcall werden folgende Aktien analysiert und erklärt:
✅ LPL Finance
✅ Blackstone
✅ Ares Management
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Aktien in diesem Artikel
| Zealand Pharma A-S | 98.92 | 5.11% |
|
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
SMI wenig bewegt erwartet -- DAX tiefer erwartet -- Asiens Börsen mehrheitlich im PlusDer heimische Aktienmarkt soll zum Wochenbeginn vorsichtig in den Handel starten. Der deutsche Aktienmarkt wird mit leichten Verlusten erwartet. Die asiatischen Indizes verzeichnen am Montag mehrheitlich Gewinne.
finanzen.net News
| Datum | Titel |
|---|---|
|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |